Warner Chilcott buys P&G Rx drugs division for $3.1 billion

Share this article:
Warner Chilcott will pay Procter & Gamble $3.1 billion for the consumer products giant's prescription drug division, including Actonel, for osteoporosis, and Asacol HD, for ulcerative colitis.

The deal gives Warner Chilcott, an Irish firm specializing in derm and women's health treatments, a small and aging but profitable portfolio of drugs that generated revenues of around $2.3 billion and net income of around $540 million for the year to June 30. Warner Chilcott also expands its presence in specialty markets and gets access to new physician offices in 14 countries. Most of the unit's 2,300 employees are expected to move to Warner Chilcott, tripling the size of the company's staff.

“Keeping the sales force focused is the most critical element of the plan,” said Warner Chilcott president and CEO Roger Boissonneault, who noted that in addition to expanding the company's US and European footprint, the deal adds gastroenterology to the firm's portfolio and bolsters its urology sales force ahead of its planned launch into the market for erectile dysfunction drugs.
Share this article:

Email Newsletters

More in News

Five things for pharma marketers to know: Friday, August 22

Five things for pharma marketers to know: Friday, ...

Two new indications give Eliquis more juice, a new rule is making hydrocodone harder to get and the ALS Ice Bucket Challenge highlights a controversial aspects of drug discovery and ...

Lilly takes on Amgen's Enbrel

Lilly takes on Amgen's Enbrel

Phase-III tests indicate Lilly's experimental treatment bests Amgen's for moderate-to-severe plaque psoriasis.

GSK Ellipta franchise expands

GSK Ellipta franchise expands

The FDA has approved Arnuity Ellipta for asthma.